UroToday9d
mCRPC with Bone Metastasis
There are currently, however, two radioligands that are United States Food and Drug Administration (FDA)-approved for the treatment of mCRPC patients: Patients with advanced prostate cancer are at ...
UroToday11d
Clarity to Present COBRA and CLARIFY Abstracts at Two World-Leading Conferences
Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...
UroToday3d
Transformative or Transitional? Deciphering the Role of NIAGARA in Shaping Future Practice - Beyond the Abstract
The phase 3 NIAGARA trial has introduced promising advancements in the treatment landscape for muscle-invasive bladder cancer (MIBC). By integrating perioperative durvalumab with neoadjuvant cisplatin ...
UroToday3d
Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer.
Enzalutamide is a potent second-generation antiandrogen commonly used to treat hormone-sensitive and castration-resistant prostate cancer (CRPC) patients. While initially effective, the disease almost ...
UroToday3d
AI Allows Pre-Screening of FGFR3 Mutational Status Using Routine Histology Slides of Muscle-Invasive Bladder Cancer - Beyond the Abstract
Urothelial carcinoma (UC) of the bladder ranks among the most prevalent malignancies worldwide, with a particularly high incidence in males. A majority of patients initially present with non-muscle ...
UroToday3d
Impact of late effects after treatment for bladder cancer with radical cystectomy on Quality of life: a case-control study.
The gold standard when treating muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC), a procedure that holds the potential to affect the function of several pelvic organs, causing an ...
UroToday3d
Development of point-of-care tests for urinary bladder cancer - an historic review and view to future prospectives.
Urine is an attractive biospecimen for noninvasive tests to facilitate bladder tumor diagnostics. Three different point-of-care (POC) tests based on lateral flow immunoassays (LFAs) are currently ...
UroToday3d
New Mediastinal and Hilar Lymphadenopathy After Adjuvant Pembrolizumab in a Patient With Stage III Clear Cell Renal Cell Carcinoma.
The advent of immune checkpoint inhibitors (ICIs) has transformed the management of advanced and high-risk renal cell carcinoma (RCC). In the adjuvant setting, ICIs, such as pembrolizumab, aim to ...
UroToday3d
MAPK1IP1L::TFE3-rearranged renal cell carcinoma: a novel fusion adding to the differential diagnosis of oncocytic renal neoplasms.
Beyond the more common TFE3 fusion partners PRCC, ASPSCR1, and SFPQ, additional less common fusion partners of TFE3-rearranged renal cell carcinoma (RCC) have been described. Herein, we present an ...
UroToday4d
Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy.
Platinum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival benefit and significant associated toxicities.
UroToday6d
Long-term effects of superselective renal artery embolization on renal function after percutaneous nephrolithotomy.
To investigate the long-term impact of superselective renal artery embolization (SRAE) on renal function in cases of severe post-percutaneous nephrolithotomy (PCNL) haemorrhage, and to identify the ...
UroToday6d
Exploring the links between gallstone disease, non-alcoholic fatty liver disease, and kidney stones: A path to comprehensive prevention.
The recent study exploring the bidirectional associations between gallstone disease, non-alcoholic fatty liver disease, and kidney stone disease highlights a critical concern in chronic disease ...